Evaluation of CCR5-Δ32 mutation and HIV-1 surveillance drug-resistance mutations in peripheral blood mononuclear cells of long-term non progressors of HIV-1-infected individuals

References

• 1. World Health Organization. HIV/AIDS. https://www.who.int/news-room/fact-sheets/detail/hiv-aids
  Google Scholar
• 2. Madec Y, Boufassa F, Avettand-Fenoel V et al. Early control of HIV-1 infection in long-term nonprogressors followed since diagnosis in the ANRS SEROCO/HEMOCO cohort. J. Acquir. Immune Defic. Syndr. 50(1), 19–26 (2009).
  MedlineGoogle Scholar
• 3. Group ISS. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N. Engl. J. Med. 373(9), 795–807 (2015).
  MedlineGoogle Scholar
• 4. Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect. Genet. Evol. 46, 292–307 (2016).
  Medline CASGoogle Scholar
• 5. Abram ME, Ferris AL, Das K et al. Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication. J. Virol. 88(13), 7589–7601 (2014).
  MedlineGoogle Scholar
• 6. Migueles SA, Connors M. Success and failure of the cellular immune response against HIV-1. Nat. Immunol. 16(6), 563–570 (2015).
  Medline CASGoogle Scholar
• 7. Kwok AJ, Mentzer A, Knight JC. Host genetics and infectious disease: new tools, insights and translational opportunities. Nat. Rev. Genet. 22(3), 137–153 (2021).
  Medline CASGoogle Scholar
• 8. Naranbhai V, Carrington M. Host genetic variation and HIV disease: from mapping to mechanism. Immunogenetics 69(8–9), 489–498 (2017).
  Medline CASGoogle Scholar
• 9. Mclaren PJ, Carrington M. The impact of host genetic variation on infection with HIV-1. Nat. Immunol. 16(6), 577–583 (2015).
  Medline CASGoogle Scholar
• 10. Monaco DC, Ende Z, Hunter E. Virus-host gene interactions define HIV-1 disease progression. Viruses Genes Cancer 31–63 (2017).
  Google Scholar
• 11. Olson AD, Meyer L, Prins M et al. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. PloS ONE 9(1), e86719 (2014).
  MedlineGoogle Scholar
• 12. Leon A, Perez I, Ruiz-Mateos E et al. Rate and predictors of progression in elite and viremic HIV-1 controllers. AIDS 30(8), 1209–1220 (2016).
  Medline CASGoogle Scholar
• 13. Goujard C, Chaix ML, Lambotte O et al. Spontaneous control of viral replication during primary HIV infection: when is “HIV controller” status established? Clin. Infect. Dis. 49(6), 982–986 (2009).
  MedlineGoogle Scholar
• 14. Durand CM, O'connell KA, Apuzzo LG et al. HIV-1 Gag evolution in recently infected human leukocyte antigen-B*57 patients with low-level viremia. AIDS 24(15), 2405–2408 (2010).
  Medline CASGoogle Scholar
• 15. Salgado M, Brennan TP, O'connell KA et al. Evolution of the HIV-1 nef gene in HLA-B*57 positive elite suppressors. Retrovirology 7(1), 1–7 (2010).
  MedlineGoogle Scholar
• 16. Migueles SA, Mendoza D, Zimmerman MG et al. CD8+ T-cell cytotoxic capacity associated with human immunodeficiency virus-1 control can be mediated through various epitopes and human leukocyte antigen types. EBioMedicine 2(1), 46–58 (2015).
  MedlineGoogle Scholar
• 17. Migueles SA, Weeks KA, Nou E et al. Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J. Virol. 83(22), 11876–11889 (2009).
  Medline CASGoogle Scholar
• 18. Qidwai T. Chemokine genetic polymorphism in human health and disease. Immunol. Lett. 176, 128–138 (2016).
  Medline CASGoogle Scholar
• 19. Armani-Tourret M, Zhou Z, Gasser R et al. Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis. PLoS Pathog. 17(4), e1009526 (2021).
  Medline CASGoogle Scholar
• 20. Weinberger AD, Perelson AS. Persistence and emergence of X4 virus in HIV infection. Math. Biosci. Eng. 8(2), 605 (2011).
  MedlineGoogle Scholar
• 21. Khorramdelazad H, Hakimizadeh E, Hassanshahi G, Rezayati M, Sendi H, Arababadi MK. CCR5 Δ 32 mutation is not prevalent in Iranians with chronic HBV infection. J. Med. Virol. 85(6), 964–968 (2013).
  Medline CASGoogle Scholar
• 22. Hütter G, Blüthgen C, Elvers-Hornung S, Klüter H, Bugert P. Distribution of the CCR5-delta32 deletion in southwest Germany. Anthropol. Anz. 72(3), 303–309 (2015).
  MedlineGoogle Scholar
• 23. Contento RL, Molon B, Boularan C et al. CXCR4–CCR5: a couple modulating T cell functions. Proc. Natl Acad. Sci. USA 105(29), 10101–10106 (2008).
  Medline CASGoogle Scholar
• 24. Allers K, Schneider T. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy. Curr. Opin. Virol. 14, 24–29 (2015).
  Medline CASGoogle Scholar
• 25. Pereyra F, Addo MM, Kaufmann DE et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197(4), 563–571 (2008).
  MedlineGoogle Scholar
• 26. Tebas P, Stein D, Tang WW et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370(10), 901–910 (2014).
  Medline CASGoogle Scholar
• 27. Smoleń-Dzirba J, Rosińska M, Janiec J et al. HIV-1 infection in persons homozygous for CCR5-Δ32 allele: the next case and the review. AIDS Rev. 19(4), 219–230 (2017).
  MedlineGoogle Scholar
• 28. Ronsard L, Sood V, Yousif AS et al. Genetic polymorphisms in the open reading frame of the CCR5 gene from HIV-1 seronegative and seropositive individuals from national capital regions of india. Sci. Rep. 9(1), 1–9 (2019).
  Medline CASGoogle Scholar
• 29. Solloch UV, Lang K, Lange V, Böhme I, Schmidt AH, Sauter J. Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers. Hum. Immunol. 78(11–12), 710–717 (2017).
  Medline CASGoogle Scholar
• 30. Heydarifard Z, Tabarraei A, Moradi A. Polymorphisms in CCR5Δ32 and risk of HIV-1 Infection in the southeast of Caspian Sea, Iran. Dis. Markers 2017, (2017).
  MedlineGoogle Scholar
• 31. Donyavi T, Bokharaei-Salim F, Nahand JS et al. Evaluation of CCR5-Δ32 mutation among individuals with high risk behaviors, neonates born to HIV-1 infected mothers, HIV-1 infected individuals, and healthy people in an Iranian population. J. Med. Virol. 92(8), 1158–1164 (2020).
  Medline CASGoogle Scholar
• 32. Vahabpour R, Bokharaei-Salim F, Kalantari S et al. HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals. Arch. Virol. 162(6), 1477–1485 (2017).
  Medline CASGoogle Scholar
• 33. Nissen SK, Christiansen M, Helleberg M et al. Whole exome sequencing of HIV-1 long-term non-progressors identifies rare variants in genes encoding innate immune sensors and signaling molecules. Sci. Rep. 8(1), 1–15 (2018).
  Medline CASGoogle Scholar
• 34. Reynoso R, Laufer N, Hackl M et al. MicroRNAs differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro. Sci. Rep. 4, 5915 (2014).
  Medline CASGoogle Scholar
• 35. Sadri Nahand J, Bokharaei-Salim F, Karimzadeh M et al. MicroRNAs and exosomes: key players in HIV pathogenesis. HIV Med. 21(4), 246–278 (2020).
  MedlineGoogle Scholar
• 36. Berg MG, Olivo A, Harris BJ et al. A high prevalence of potential HIV elite controllers identified over 30 years in Democratic Republic of Congo. EBioMedicine 65, 103258 (2021).
  Medline CASGoogle Scholar
• 37. Solomon SS, Solomon S, McFall AM et al. Integrated HIV testing, prevention, and treatment intervention for key populations in India: a cluster-randomised trial. Lancet HIV 6(5), e283–e296 (2019).
  MedlineGoogle Scholar
• 38. Madec Y, Boufassa F, Porter K et al. Natural history of HIV-control since seroconversion. AIDS 27(15), 2451–2460 (2013).
  MedlineGoogle Scholar
• 39. Cooper DA, Heera J, Ive P et al. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings. AIDS (London, England) 28(5), 717 (2014).
  Medline CASGoogle Scholar
• 40. Petrucci A, Dorrucci M, Alliegro MB et al. How many HIV-infected individuals may be defined as long-term nonprogressors? A report from the Italian Seroconversion Study. J. Acquir. Immune Defic. Syndr. 14(3), 243–248 (1997).
  CASGoogle Scholar
• 41. Han J, Wu Z, Mcgoogan JM et al. Overrepresentation of injection drug use route of infection among human immunodeficiency virus long-term nonprogressors: a nationwide, retrospective cohort study in China, 1989–2016. Open Forum Infect. Dis. 6(5), ofz182 (2019).
  MedlineGoogle Scholar
• 42. Telele NF, Kalu AW, Marrone G et al. Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia. PloS ONE 13(7), e0200505 (2018).
  MedlineGoogle Scholar
• 43. Shoko C, Chikobvu D. A superiority of viral load over CD4 cell count when predicting mortality in HIV patients on therapy. BMC Infect. Dis. 19(1), 1–10 (2019).
  MedlineGoogle Scholar
• 44. Kayongo A, Gonzalo-Gil E, Gümüşgöz E et al. Brief report: identification of elite and viremic controllers from a large urban HIV ambulatory center in Kampala, Uganda. J. Acquir. Immune Defic. Syndr. 79(3), 394 (2018).
  MedlineGoogle Scholar
• 45. Laeyendecker O, Redd AD, Lutalo T et al. Frequency of long-term nonprogressors in HIV-1 seroconverters from Rakai, Uganda. J. Acquir. Immune Defic. Syndr. 52(3), 316 (2009).
  MedlineGoogle Scholar
• 46. Bokharaei-Salim F, Esghaei M, Khanaliha K et al. HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naïve HIV-infected individuals. Plos ONE 15(3), e0229275 (2020).
  Medline CASGoogle Scholar
• 47. Marjani A, Bokharaei-Salim F, Jahanbakhshi F et al. HIV-1 integrase drug-resistance mutations in Iranian treatment-experienced HIV-1-infected patients. Arch. Virol. 165(1), 115–125 (2020).
  Medline CASGoogle Scholar
• 48. Jarchi M, Bokharaei-Salim F, Esghaei M et al. The frequency of HIV-1 infection in iranian children and determination of the transmitted drug resistance in treatment-naïve children. Current HIV Res. 17(6), 397–407 (2019).
  Medline CASGoogle Scholar
• 49. Mozhgani SH, Ebrahimian SA, Gudarzi H et al. CRF35-AD as the main circulating genotype of human immunodeficiency virus type 1 infection in Iran: a phylogenetic and demographic-based study. Intervirology 60(4), 144–148 (2017).
  Medline CASGoogle Scholar
• 50. Vahabpour R, Bokharaei-Salim F, Kalantari S et al. HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals. Arch. Virol. 162(6), 1477–1485 (2017).
  Medline CASGoogle Scholar
• 51. Jahanbakhsh F, Hattori J, Matsuda M et al. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. PloS ONE 8(4), e61864 (2013).
  Medline CASGoogle Scholar
• 52. Arenzana-Seisdedos F, Parmentier M. Genetics of resistance to HIV infection: role of co-receptors and co-receptor ligands. Semin. Immunol. 18(6), 387–403 (2006).
  Medline CASGoogle Scholar
• 53. Poropatich K, Sullivan DJ Jr. Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. J. Gen. Virol. 92(2), 247–268 (2011).
  Medline CASGoogle Scholar
• 54. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273(5283), 1856–1862 (1996).
  Medline CASGoogle Scholar
• 55. Stewart GJ, Ashton LJ, Biti RA et al. Increased frequency of CCR-5 Δ32 heterozygotes among long-term non-progressors with HIV-1 infection. AIDS 11(15), 1833–1838 (1997).
  Medline CASGoogle Scholar
• 56. Michael NL, Chang G, Loum LG et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat. Med. 3(3), 338–340 (1997).
  Medline CASGoogle Scholar
• 57. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nat. Genet. 16(1), 100–103 (1997).
  Medline CASGoogle Scholar
• 58. Fahrioglu U, Ergoren MC, Mocan G. CCR5-Δ32 gene variant frequency in the Turkish Cypriot population. Braz. J. Microbiol. 1–7 (2020).
  MedlineGoogle Scholar
• 59. Rahimi H, Farajollahi MM, Hosseini A. Distribution of the mutated delta 32 allele of CCR5 co-receptor gene in Iranian population. Med. J. Islam. Repub. Iran 28, 140 (2014).
  MedlineGoogle Scholar
• 60. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27(3), 406–416 (2007).
  Medline CASGoogle Scholar
• 61. Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J. Acquir. Immune Defic. Syndr. 55(2), 148 (2010).
  Medline CASGoogle Scholar
• 62. Nakahara K, Wakasa-Morimoto C, Kobayashi M et al. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antivir. Res. 81(2), 141–146 (2009).
  Medline CASGoogle Scholar
• 63. Svarovskaia ES, Feng JY, Margot NA et al. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J. Acquir. Immune Defic. Syndr. 48(4), 428–436 (2008).
  Medline CASGoogle Scholar
• 64. Miura T, Brumme ZL, Brockman MA et al. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J. Virol. 84(15), 7581–7591 (2010).
  Medline CASGoogle Scholar
• 65. Walker-Sperling VE, Pohlmeyer CW, Veenhuis RT et al. Factors associated with the control of viral replication and virologic breakthrough in a recently infected HIV-1 controller. EBioMedicine 16, 141–149 (2017).
  MedlineGoogle Scholar
• 66. Yang OO, Cumberland WG, Escobar R, Liao D, Chew KW. Demographics and natural history of HIV-1-infected spontaneous controllers of viremia: extremes on a continuum. AIDS (London, England) 31(8), 1091 (2017).
  Medline CASGoogle Scholar
• 67. Meier A, Chang JJ, Chan ES et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat. Med. 15(8), 955–959 (2009).
  Medline CASGoogle Scholar
• 68. Ruel TD, Zanoni BC, Ssewanyana I et al. Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin. Infect. Dis. 53(6), 592–599 (2011).
  Medline CASGoogle Scholar
• 69. Newell ML, Giaquinto C, Rampon O et al. Level and pattern of HIV-1-RNA viral load over age: differences between girls and boys? AIDS (London, England) 16(1), 97–104 (2002).
  MedlineGoogle Scholar
• 70. Mori M, Adland E, Paioni P et al. Sex differences in antiretroviral therapy initiation in pediatric HIV infection. PloS ONE 10(7), e0131591 (2015).
  MedlineGoogle Scholar
• 71. Okulicz JF, Lambotte O. Epidemiology and clinical characteristics of elite controllers. Curr. Opin. HIV AIDS 6(3), 163–168 (2011).
  MedlineGoogle Scholar